Affinomer
A sensing platform that utilizes the bleeding edge of Molecularly Imprinted Polymers (MIPs) for rapid, reliable and cost-effective detection of disease biomarkers, chemical contaminants, and molecules of interest.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
N/A | - | ||
| Total Funding | 000k | ||
Related Content
Affinomer is a pioneering startup focused on revolutionizing point-of-care chemical sensing through innovative technology. Unlike traditional methods that rely on antibodies, Affinomer utilizes Molecularly Imprinted Polymers (MIPs). MIPs are synthetic materials designed to mimic the structure of specific molecules, making them highly effective for chemical sensing. These polymers are robust, capable of withstanding extreme pH levels and temperatures, which makes them more durable than traditional biological sensors.
Affinomer aims to transition MIP technology from academic research to commercial applications. Currently, MIPs are primarily used in research labs, but Affinomer is working to integrate these synthetic receptors into practical devices such as lateral flow devices, biosensing platforms, and in vitro diagnostics (IVD) systems. These applications are crucial for sample preparation, purification, and enrichment processes in various industries.
The company serves a diverse range of clients, including healthcare providers, diagnostic labs, and research institutions. By offering a more reliable and versatile sensing technology, Affinomer addresses the needs of these clients for accurate, efficient, and cost-effective diagnostic solutions.
Affinomer operates in the healthcare and biotechnology market, focusing on point-of-care diagnostics and chemical sensing. The business model revolves around developing and commercializing MIP-based biosensors and diagnostic devices. Revenue is generated through the sale of these advanced sensing products and potentially through licensing agreements with other companies interested in incorporating MIP technology into their own products.
In summary, Affinomer is set to transform the field of chemical sensing with its innovative MIP technology, providing robust and versatile solutions for point-of-care diagnostics.
Keywords: Molecularly Imprinted Polymers, chemical sensing, point-of-care, diagnostics, biosensors, healthcare, biotechnology, synthetic receptors, lateral flow devices, in vitro diagnostics.